BUTABARBITAL SODIUM

US Previously Marketed

First approved in 1939

Details

Stereochemistry	RACEMIC
Molecular Formula	C10H15N2O3.Na
Molecular Weight	234.2275
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O

InChI

InChIKey=QORQZMBCPRBCAB-UHFFFAOYSA-M

InChI=1S/C10H16N2O3.Na/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14;/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/000793s025lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10209232

Barbiturates are non-selective depressants of the central nervous system. Butabarbital is one of them, which is used under brand name butisol sodium as a sedative or hypnotic. Like other barbiturates, butabarbital is capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. The mechanism of action by which barbiturates exert their effect is not yet completely understood, but is assumed, that butabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; anion channel 203 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11264449	Positive Allosteric Modulator 186

Conditions

Condition	Modality	Targets	Highest Phase	Product
Sleeplessness 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/000793s025lbl.pdf	Primary		Approved 8583	BUTISOL SODIUM Approved Use BUTISOL SODIUM (butabarbital sodium tablets, USP and butabarbital sodium oral solution, USP) is indicated for use as a sedative or hypnotic. Since barbiturates appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks, use of BUTISOL SODIUM in treating insomnia should be limited to this time. Launch Date 1939

Doses

Dose	Population	Adverse events
15 mg 4 times / day multiple, oral Recommended Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4262210/	unhealthy, 36 Health Status: unhealthy Age Group: 36 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4262210/	Disc. AE: Drowsiness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4262210/
30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/	Other AEs: Sedation... Other AEs: Sedation (10 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/
30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/	Other AEs: Sedation... Other AEs: Sedation (14 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/

AEs

AE	Significance	Dose	Population
Drowsiness	1 patient Disc. AE	15 mg 4 times / day multiple, oral Recommended Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4262210/	unhealthy, 36 Health Status: unhealthy Age Group: 36 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4262210/
Sedation	10 patients	30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/
Sedation	14 patients	30 mg 4 times / day multiple, oral Recommended Dose: 30 mg, 4 times / day Route: oral Route: multiple Dose: 30 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/4913869/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1197

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 2633	inducer 1966 Sources: https://www.wellrx.com/butisol%20sodium/monographs/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30443785/ Page: 11.0	yes
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30443785/ Page: 11.0	yes

Sourcing

Vendor/Aggregator	ID	URL
Alsachim	3096	http://www.alsachim.com/product-C4174-glo.bal-view.html
Aurora Fine Chemicals LLC	A17.920.718	http://online.aurorafinechemicals.com/info?ID=A17.920.718
Avantor Inc	75835-278	https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
Chem Scene	CS-7224	http://www.chemscene.com/125-40-6.html
ChemMol	30105098	http://www.chemmol.com/chemmol/30105098.html
ChemMol	49415741	http://www.chemmol.com/chemmol/49415741.html
Clearsynth	CS-EB-00333	https://www.clearsynth.com/en/CSEB00333.html
Clearsynth	CS-ER-00325	https://www.clearsynth.com/en/CSER00325.html
MedChem Express	HY-U00167	http://www.medchemexpress.com/NSC27517.html
Sigma-Aldrich	B-024_CERILLIAN	http://www.sigmaaldrich.com/catalog/product/cerillian/b024?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S522301	http://www.smolecule.com/products/s522301
THE BioTek	bt-262147	https://www.thebiotek.com/product/inhibitors/bt-262147

PubMed

Title	Date	PubMed
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.	2010	22291486
Management of acute diarrhoea in primary care in Bahrain: self-reported practices of doctors.	2007-06	17985822
Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats.	2007-04-30	17291486
The history of barbiturates a century after their clinical introduction.	2005-12	18568113
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.	2003-06	12826989

Sample Use Guides

In Vivo Use Guide

Usual adult dosage: daytime sedative - 15 to 30 mg, 3 or 4 times daily. Bedtime hypnotic - 50 to 100 mg. Preoperative sedative - 50 to 100 mg, 60 to 90 minutes before surgery. Usual pediatric dosage: preoperative sedative - 2 to 6 mg/kg maximum 100 mg.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

BUTABARBITAL SODIUM

Common Name

English

SECBUTABARBITAL SODIUM

Preferred Name

English

2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(1-METHYLPROPYL)-, SODIUM SALT (1:1)

Systematic Name

English

LOUBARB

Brand Name

English

BUTISOL SODIUM

Brand Name

English

BUTABARBITAL SODIUM [VANDF]

Common Name

English

BUTABARBITAL SODIUM [ORANGE BOOK]

Common Name

English

Sodium 5-sec-butyl-5-ethylbarbiturate

Systematic Name

English

BUTABARBITAL SODIUM [USP MONOGRAPH]

Common Name

English

SARISOL

Brand Name

English

2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(1-METHYLPROPYL)-, MONOSODIUM SALT

Common Name

English

BUTICAPS

Brand Name

English

BUTABARBITAL SODIUM SALT

Common Name

English

BUTABARB

Brand Name

English

ASTRUDION

Brand Name

English

BUTABARBITAL SODIUM SALT [MI]

Common Name

English

MEBUTAL

Brand Name

English

SECBUTABARBITAL SODIUM [MART.]

Common Name

English

NSC-11778

Code

English

Secbutabarbital sodium [WHO-DD]

Common Name

English

BUTALAN

Brand Name

English

Classification Tree Code System Code

DEA NO.

2100